Heron Therapeutics Inc (HRTX) to Post FY2019 Earnings of ($0.23) Per Share, Oppenheimer Forecasts
Heron Therapeutics Inc (NASDAQ:HRTX) – Investment analysts at Oppenheimer cut their FY2019 earnings per share (EPS) estimates for shares of Heron Therapeutics in a research note issued on Monday. Oppenheimer analyst D. Archila now anticipates that the biotechnology company will post earnings of ($0.23) per share for the year, down from their previous estimate of ($0.20). Oppenheimer currently has a “Buy” rating and a $34.00 target price on the stock. Oppenheimer also issued estimates for Heron Therapeutics’ FY2022 earnings at $5.03 EPS.
A number of other equities analysts also recently commented on HRTX. Noble Financial restated a “buy” rating on shares of Heron Therapeutics in a report on Wednesday. Needham & Company LLC increased their price objective on Heron Therapeutics to $42.00 and gave the stock a “buy” rating in a report on Tuesday. Cowen restated a “buy” rating on shares of Heron Therapeutics in a report on Monday. Mizuho restated a “buy” rating and issued a $35.00 price objective (up previously from $28.00) on shares of Heron Therapeutics in a report on Monday. Finally, Cantor Fitzgerald set a $40.00 price objective on Heron Therapeutics and gave the stock a “buy” rating in a report on Monday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $33.00.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.29). The company had revenue of $10.05 million during the quarter, compared to analysts’ expectations of $9.00 million. Heron Therapeutics had a negative return on equity of 230.70% and a negative net margin of 641.87%.
In other Heron Therapeutics news, VP Kimberly Manhard sold 7,584 shares of the stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $20.00, for a total transaction of $151,680.00. Following the transaction, the vice president now owns 7,584 shares in the company, valued at $151,680. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Barry D. Quart sold 100,000 shares of the stock in a transaction that occurred on Wednesday, March 14th. The shares were sold at an average price of $24.75, for a total value of $2,475,000.00. Following the transaction, the chief executive officer now owns 167,993 shares in the company, valued at approximately $4,157,826.75. The disclosure for this sale can be found here. In the last quarter, insiders have sold 225,584 shares of company stock worth $6,141,680. Corporate insiders own 19.93% of the company’s stock.
Hedge funds have recently made changes to their positions in the business. Ellington Management Group LLC acquired a new stake in shares of Heron Therapeutics in the fourth quarter worth $195,000. Pinnacle Associates Ltd. acquired a new stake in shares of Heron Therapeutics in the fourth quarter worth $201,000. Trexquant Investment LP acquired a new stake in shares of Heron Therapeutics in the third quarter worth $206,000. Jefferies Group LLC acquired a new stake in shares of Heron Therapeutics in the fourth quarter worth $214,000. Finally, Jane Street Group LLC acquired a new stake in shares of Heron Therapeutics in the third quarter worth $223,000.
ILLEGAL ACTIVITY WARNING: “Heron Therapeutics Inc (HRTX) to Post FY2019 Earnings of ($0.23) Per Share, Oppenheimer Forecasts” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.watchlistnews.com/heron-therapeutics-inc-hrtx-to-post-fy2019-earnings-of-0-23-per-share-oppenheimer-forecasts/1961306.html.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.